体外膜氧合与新型冠状病毒肺炎:能否降低死亡率?

Does extracorporeal membrane oxygenation reduce mortality in novel coronavir us pneumonia?

2019新型冠状病毒肺炎(COVID-19)在我国爆发流行并对国际公共卫生健康造成巨大威胁,大部分危重患者临床表现为急性呼吸窘迫综合征(ARDS)。体外膜氧合技术(ECMO)是目前严重ARDS患者的终极挽救性救治手段。回顾ECMO相关经典文献,总结ECMO在甲型流感(H1N1)、SARS以及中东呼吸综合征患者救治中的作用,在COVID-19目前尚无特效治疗手段的情况下,ECMO作为常规治疗无效的挽救性治疗可能会对危重患者有益。

Since the end of 2019,an outbreak of pneumonia caused by a novel coronavirus named 2019 novel coronavirus pneumonia(COVID-19)has occurred in China.COVID-19,which has spread fast to a few countries by now,has posed an enormous threat to international health.Coronavirus infection can cause severe respiratory distress syndrome(ARDS).Veno-venous extracorpore al membrane oxygenation(V-V ECMO)can provide effective respiratory support immediately and it is regarded as the ultimate means for severe ARDS.According to the data of influenza or MERS-CoV-related ARDS and the result of CESAR and EOLIA clinical trial,V-V ECMO should be considered in viral related severe ARDS.In the absence of specific treatment for COVID-19,V-V ECMO could be a reasonable treatment for severe ARDS with failure of optimized ventilation.